Association between Genetic Polymorphisms in RANK, RANKL and OPG and Peri-Implant Diseases in Patients from the Amazon Region

Abstract

The present study evaluated polymorphisms in RANK, RANKL and OPG-encoding genes to assess whether they are associated with mucositis and peri-implantitis in a population from the Brazilian Amazon region. One hundred and fourteen patients with dental implants were included in the study. After clinical and radiographic examination, the sample was categorized into 4 groups, according to the peri-implant status: Healthy (n=71), Mucositis (n=30), Peri-implantitis (n=13) and Diseased (Mucositis + Peri-implantitis, n=43). Genomic DNA was extracted from buccal cells from saliva, and the genetic polymorphism in osteoprotegerin (OPG), Kappa nuclear factor activator receptor (RANKL) and nuclear kappa factor activator receptor (RANK) were genotyped by the real time PCR. Univariate and multivariate statistical analyses were performed to compare clinical variables among groups and to evaluate genotypes and alleles distributions and the established alpha was 5%. Age, peri-implant biotype, diabetes and presence of peri-implant biofilm were associated with mucositis (p<0.05) and peri-implantitis (p<0.05). Smoking, alcoholism, and periodontal biofilms were also associated with the presence of peri-implantitis (p<0.05). Univariate and multivariate analysis did not demonstrate an association of peri-implantitis or mucositis with any genetic polymorphism in RANK (rs3826620), RANKL (rs9594738) and OPG (rs2073618) (p>0.05). The studied genetic polymorphism in RANK, RANKL and OPG were not associated with mucositis and peri-implantitis in a Brazilian population from the Amazon region.

Association between Interleukin-1 Polymorphisms and Susceptibility to Dental Peri-Implant Disease: A Meta-Analysis

“…Three published meta-analyses [10][11][12][13][14][15][16][17][18][19][20][21][22] investigated the association between the IL−1 polymorphisms and the risk of PIDs. Junior et al [21] reported just two articles and reported that there was no association between IL−1B (−511) polymorphism and the risk of implant failure based on the allelic model.…”

“…In this view, meta-analyses [6][7][8][9][10], reviews [11], and original articles [12,13] demonstrated the role of several polymorphisms in PIDs. Proinflammatory cytokines, such as interleukins (ILs), are important biochemical mediators to control the host response to inflammation and to also stimulate the production and secretion of prostaglandins.…”

“…IL−1 is composed of 11 genes in the 430-kb fragment in the long arm DNA of chromosome 2, in the 2q12-q21 region. These genes produce the IL−1 alpha (IL−1A) and IL−1 beta (IL−1B) with genetic and biochemical differences but with the same biological functions [10][11][12][13][14][15][16]. IL−1 receptor antagonist (IL−1RN) gene regulates the synthesis of the IL−1ra antagonist protein, which can disrupt IL−1A and IL−1B function in competition for receptor binding [17].…”

“…A thorough literature search identified five systematic reviews [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] and three metaanalyses [10][11][12][13][14][15][16][17][18][19][20][21][22] focusing on the associations between IL−1 polymorphisms and PIDs. Among these meta-analyses, one meta-analysis [10] included the highest number of articles (13 articles) and reported an association between the occurrence of IL−1A (−889), IL−1B (−511), and IL−1B (+3954) polymorphisms in patients with PIDs.…”

Network pharmacology combined with GEO database identifying the mechanisms and molecular targets of Polygoni Cuspidati Rhizoma on Peri-implants

“…Peri-implant, which refers to inflammatory damage to the hard and soft tissues around implants, including peri-implant mucositis and peri-implants inflammation. Peri-implant mucositis is limited to the surrounding soft tissue, rather Peri-implants could penetrate into the implants and cause severe bone resorption, if left untreated, can cause the loss of the implant 1 . Recent studies have shown that up to 56% of implant patients and even 43% of implant sites are affected by Peri-implants 2 .…”